The effects of telomerase inhibition on prostate tumor-initiating cells

International Journal of Cancer

Volumn 127, Issue 2, 2010, Pages 321-331

  Marian, Calin O ^a   Wright, Woodring E ^a   Shay, Jerry W ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Cancer stem cells; Imetelstat; Prostate; Telomerase

Indexed keywords

CD133 ANTIGEN; GRN 163L; HERMES ANTIGEN; HOE 33342; IMETELSTAT; TELOMERASE; TELOMERASE INHIBITOR; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 2; DRUG DERIVATIVE; INDOLE DERIVATIVE; MOTESANIB; NICOTINAMIDE; STEM CELL FACTOR RECEPTOR; TERT PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CANCER RELAPSE; CELL ISOLATION; CELL STRAIN LNCAP; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; TELOMERE; TUMOR CELL; CANCER STEM CELL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; HUMANS; INDOLES; MALE; NEOPLASTIC STEM CELLS; NIACINAMIDE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT; SPHEROIDS, CELLULAR; TELOMERASE; TELOMERE;

EID: 77953699259     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25043     Document Type: Article

References (62)

1. Mike S, Harrison C, Coles B, Staffurth J, Wilt TJ, Mason MD. Chemotherapy for hormone-refractory prostate cancer.Cochrane Database Syst Rev (Online) 2006:CD005247.
2. Uzzo RG, Haas NB, Crispen PL, Kolenko VM. Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer. Cancer 2008;112:1660-71.
3. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res 2006;66:1883-90, discussion 95-6. (Pubitemid 43294892)
4. Ward RJ, Dirks PB. Cancer stem cells: at the headwaters of tumor development. Annu Rev Pathol 2007;2:175-89.
5. Sabbath KD, Ball ED, Larcom P, Davis RB, Griffin JD. Heterogeneity of clonogenic cells in acute myeloblastic leukemia. J Clin Invest 1985;75:746-53. (Pubitemid 15142089)
6. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977;197:461-63.
7. Liu AY, True LD, LaTray L, Nelson PS, Ellis WJ, Vessella RL, Lange PH, Hood L, van den Engh G. Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci USA 1997;94:10705-10.
8. Avigdor A, Goichberg P, Shivtiel S, Dar A, Peled A, Samira S, Kollet O, Hershkoviz R, Alon R, Hardan I, Ben-Hur H, Naor D, et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood 2004;103:2981-9.
9. Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M, Werner C. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004;22:377-84. (Pubitemid 38736621)
10. Schwartz PH, Bryant PJ, Fuja TJ, Su H, O'Dowd DK, Klassen H. Isolation and characterization of neural progenitor cells from post-mortem human cortex. J Neurosci Res 2003;74:838-51. (Pubitemid 37490416)
11. Gudjonsson T, Villadsen R, Nielsen HL, Ronnov-Jessen L, Bissell MJ, Petersen OW. Isolation, immortalization, and characterization of a human breast epithelial cell line with stem cell properties. Genes Dev 2002;16:693-706. (Pubitemid 34274039)
12. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008;98:756-65.
13. Patrawala L, Calhoun T, Schneider- Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25:1696-708.
14. Collins AT, Habib FK, Maitland NJ, Neal DE. Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci 2001;114:3865-72.
15. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res 2007;67:6796-805. (Pubitemid 47105527)
16. Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 2008;68:9703-11.
17. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004;117:3539-45.
18. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-51. (Pubitemid 41713363)
19. Wei C, Guomin W, Yujun L, Ruizhe Q. Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line? Cancer Biol Ther 2007;6:763-8.
20. Brown MD, Gilmore PE, Hart CA, Samuel JD, Ramani VA, George NJ, Clarke NW. Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations. Prostate 2007;67:1384-96.
21. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005;65:6207-19. (Pubitemid 40994406)
22. Locke M, Heywood M, Fawell S, Mackenzie IC. Retention of intrinsic stem cell hierarchies in carcinoma-derived cell lines. Cancer Res 2005;65:8944-50. (Pubitemid 41377385)
23. Li H, Chen X, Calhoun-Davis T, Claypool K, Tang DG. PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res 2008;68:1820-5. (Pubitemid 351416567)
24. Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, Meyne J, Ratliff RL, Wu JR. A highly conserved repetitive DNA-sequence, (TTAGGG)n, present at the telomeres of human-chromosomes. Proc Natl Acad Sci USA 1988;85:6622-26.
25. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985;43:405-13.
26. Zhang W, Kapusta LR, Slingerland JM, Klotz LH. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res 1998;58:619-21. (Pubitemid 28099467)
27. Takahashi C, Miyagawa I, Kumano S, Oshimura M. Detection of telomerase activity in prostate cancer by needle biopsy. Eur Urol 1997;32:494-8. (Pubitemid 27501053)
28. Lin Y, Uemura H, Fujinami K, Hosaka M, Iwasaki Y, Kitamura H, Harada M, Kubota Y. Detection of telomerase activity in prostate needle-biopsy samples. Prostate 1998;36:121-8. (Pubitemid 28311316)
29. Lin Y, Uemura H, Fujinami K, Hosaka M, Harada M, Kubota Y. Telomerase activity in primary prostate cancer. J Urol 1997;157:1161-5. (Pubitemid 27066336)
30. Kallakury BV, Brien TP, Lowry CV, Muraca PJ, Fisher HA, Kaufman RP Jr, Ross JS. Telomerase activity in human benign prostate tissue and prostatic adenocarcinomas. Diagn Mol Pathol 1997;6:192-8.
31. Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 1996;56:218-22.
32. Kamradt J, Drosse C, Kalkbrenner S, Rohde V, Lensch R, Lehmann J, Fixemer T, Bonkhoff H, Stoeckle M, Wullich B. Telomerase activity and telomerase subunit gene expression levels are not related in prostate cancer: a real-time quantification and in situ hybridization study. Lab Invest 2003;83:623-33.
33. Liu BC, LaRose I, Weinstein LJ, Ahn M, Weinstein MH, Richie JP. Expression of telomerase subunits in normal and neoplastic prostate epithelial cells isolated by laser capture microdissection. Cancer 2001;92:1943-8.
34. Koga S, Hirohata S, Kondo Y, Komata T, Takakura M, Inoue M, Kyo S, Kondo S. FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo. Anticancer Res 2001;21:1937-43.
35. Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 2002;21:674-9.
36. Naasani I, Oh-Hashi F, Oh-Hara T, Feng WY, Johnston J, Chan K, Tsuruo T. Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo. Cancer Res 2003;63:824-30.
37. Sun D, Thompson B, Cathers BE, Salazar M, Kerwin SM, Trent JO, Jenkins TC, Neidle S, Hurley LH. Inhibition of human telomerase by a G-quadruplex-interactive compound. J Med Chem 1997;40:2113-6. (Pubitemid 27284346)
38. Strahl C, Blackburn EH. The effects of nucleoside analogs on telomerase and telomeres in Tetrahymena. Nucleic Acids Res 1994;22:893-900. (Pubitemid 24162147)
39. Yokoyama Y, Takahashi Y, Shinohara A, Lian Z, Wan X, Niwa K, Tamaya T. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res 1998;58:5406-10. (Pubitemid 28551123)
40. Herbert BS, Pongracz K, Shay JW, Gryaznov SM. Oligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors. Oncogene 2002;21:638-42. (Pubitemid 34146265)
41. Canales BK, Li Y, Thompson MG, Gleason JM, Chen Z, Malaeb B, Corey DR, Herbert BS, Shay JW, Koeneman KS. Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model. Urol Oncol 2006;24:141-51.
42. Asai A, Oshima Y, Yamamoto Y, Uochi TA, Kusaka H, Akinaga S, Yamashita Y, Pongracz K, Pruzan R, Wunder E, Piatyszek M, Li S, et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res 2003;63:3931-9.
43. Ozawa T, Gryaznov SM, Hu LJ, Pongracz K, Santos RA, Bollen AW, Lamborn KR, Deen DF. Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. Neuro Oncol 2004;6:218-26. (Pubitemid 39136505)
44. Herbert BS, Gellert GC, Hochreiter A, Pongracz K, Wright WE, Zielinska D, Chin AC, Harley CB, Shay JW, Gryaznov SM. Lipid modification of GRN163, an N3′→P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 2005;24:5262-8.
45. Djojosubroto MW, Chin AC, Go N, Schaetzlein S, Manns MP, Gryaznov S, Harley CB, Rudolph KL. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology 2005;42:1127-36. (Pubitemid 43112680)
46. Gellert GC, Dikmen ZG, Wright WE, Gryaznov S, Shay JW. Effects of a novel telomerase inhibitor. GRN163L, in human breast cancer. Breast Cancer Res Treat 2006;96:73-81.
47. Dikmen ZG, Gellert GC, Jackson S, Gryaznov S, Tressler R, Dogan P, Wright WE, Shay JW. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res 2005;65:7866-73.
48. Harley CB. Telomerase and cancer therapeutics. Nat Rev 2008;8:167-79.
49. Shay JW, Keith WN. Targeting telomerase for cancer therapeutics. Br J Cancer 2008;98:677-83.
50. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, Daidone MG. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005;65:5506-11. (Pubitemid 40911148)
51. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996;183:1797-806. (Pubitemid 26134320)
52. Pascal LE, Oudes AJ, Petersen TW, Goo YA, Walashek LS, True LD, Liu AY. Molecular and cellular characterization of ABCG2 in the prostate. BMC Urol 2007;7:6.
53. Holt SE, Shay JW. Role of telomerase in cellular proliferation and cancer. J Cell Physiol 1999;180:10-8.
54. Meeker AK, Gage WR, Hicks JL, Simon I, Coffman JR, Platz EA, March GE, De Marzo AM. Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am J Pathol 2002;160:1259-68. (Pubitemid 34411630)
55. Meeker AK, Hicks JL, Platz EA, March GE, Bennett CJ, Delannoy MJ, De Marzo AM. Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res 2002;62:6405-9.
56. Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, Schneider-Broussard R, Jeter C. Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol Carcinog 2007;46:1-14. (Pubitemid 46095228)
57. Guo C, Geverd D, Liao R, Hamad N, Counter CM, Price DT. Inhibition of telomerase is related to the life span and tumorigenicity of human prostate cancer cells. J Urol 2001;166:694-8. (Pubitemid 32652302)
58. Koeneman KS, Pan CX, Jin JK, Pyle JM, 3rd, Flanigan RC, Shankey TV, Diaz MO. Telomerase activity, telomere length, and DNA ploidy in prostatic intraepithelial neoplasia (PIN). J Urol 1998;160:1533-9.
59. Allen ND, Baird DM. Telomere length maintenance in stem cell populations. Biochim Biophys Acta 2009;1792:324-8.
60. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60. (Pubitemid 44949604)
61. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006;5:67. (Pubitemid 44942887)
62. Kang MK, Kang SK. Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev 2007;16:837-47.